• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Hua Medicine picks Hong Kong, S.A.R., China for IPO

biospectrumasiaMarch 12, 2018

Tag: IPO , diabetes drug , Hua Medicine

Hua Medicine, the Shanghai based diabetes drug developer, has chosen Hong Kong, S.A.R., China Special Administrative Region of China instead of U.S. for its initial public offering (IPO) for the Asian financial hub makes a push for biotech listings.

The company is working with advisers Goldman Sachs Group Inc., CLSA Ltd. and UBS Group AG on a planned offering in the city this year. The offering could raise as much as $300 million.

Hua Medicine, led by Chen Li, the former chief scientist for China at Roche Holding AG, is running late-stage clinical trials for its oral drug used for the treatment of type 2 diabetes.

Register as Visitor to CPhI China 2018!

Previous:VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock

Next:'Cancer is an increasingly important health issue in the APAC region’

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Hua Medicine picks Hong Kong, S.A.R., China for IPO | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Calcipotriol (monohydrate)

Calcipotriol (monohydrate)
Dipotassium Hydrogenphosphate

Dipotassium Hydrogenphosphate
high quality Glycyrrhizin Dipotassium Salt from GMP factory in China

high quality Glycyrrhizin Dipotassium Salt from GMP factory in China
Alpha lipoic acid powder

Alpha lipoic acid powder
Sodium Tripolyphosphate (STPP)

Sodium Tripolyphosphate (STPP)
Calcipotriol Anhydrous

Calcipotriol Anhydrous
Ultrafiltration system / liposome dialysis/LDS-L2TANGENTIAL FLOW FILTRATION

Ultrafiltration system / liposome dialysis/LDS-L2TANGENTIAL FLOW FILTRATION
Potassium Tripolyphosphate(KTPP)

Potassium Tripolyphosphate(KTPP)
Calcipotriol Impurity H

Calcipotriol Impurity H
Dipotassium Glycyrrhizinate

Dipotassium Glycyrrhizinate

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service